PDS Biotechnology Corp - SIC # 8731 - COMMERCIAL PHY_SICAL AND BIOLOGICAL RESEARCH

Ticker Exchange SIC # Website Latest Ticker
PDSB Nasdaq 8731 https://www.pdsbiotech.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for PDS Biotechnology Corp

PDS Biotechnology Corporation's (NASDAQ:PDSB) market cap dropped US$1.5m last week; individual investors who hold 59% were hit as were institutions - Mar 30th, 2024 12:35 pm
PDS Biotechnology Corporation (NASDAQ:PDSB) Q4 2023 Earnings Call Transcript - Mar 28th, 2024 2:24 pm
Q4 2023 PDS Biotechnology Corp Earnings Call - Mar 28th, 2024 3:33 am
PDS Biotechnology Corp (PDSB) Reports Full Year 2023 Financial Results and Clinical Strategy Update - Mar 27th, 2024 12:51 pm
PDS Biotech Announces Clinical Strategy Update and Reports Full Year 2023 Financial Results - Mar 27th, 2024 11:30 am
PDS Biotechnology Announces Conference Call and Webcast for Business Update and Full Year 2023 Financial Results - Mar 20th, 2024 12:00 pm
The 3 Most Undervalued Biotech Stocks to Buy in March 2024 - Mar 13th, 2024 2:55 pm
PDS Biotech Announces Publication of Preclinical Research and Grant of U.S. Composition of Matter Patent for Infectimune® - Mar 13th, 2024 12:00 pm
PDS Biotech Announces Retirement of Lauren V. Wood, M.D., and Appointment of Kirk V. Shepard, M.D., as Chief Medical Officer - Jan 22nd, 2024 9:45 pm
PDS Biotech to Participate at B. Riley Securities 4th Annual Oncology Conference - Jan 16th, 2024 1:00 pm
All You Need to Know About PDS Biotechnology (PDSB) Rating Upgrade to Buy - Jan 2nd, 2024 5:00 pm
PDS Biotechnology Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) - Dec 4th, 2023 9:50 pm
PDS Biotech Appoints Lars Boesgaard as Chief Financial Officer - Nov 28th, 2023 12:30 pm
PDS Biotechnology Corporation (NASDAQ:PDSB) Q3 2023 Earnings Call Transcript - Nov 15th, 2023 6:03 pm
PDS Biotechnology Corp (PDSB) Reports Increased Net Loss in Q3 2023 Amid Advancements in ... - Nov 14th, 2023 5:19 pm
PDS Biotech Reports Third Quarter 2023 Financial Results and Provides Business Update - Nov 14th, 2023 12:30 pm
PDS Biotech Announces Updated Survival Data from NCI-Led Phase 2 Clinical Trial of PDS0101-Based Triple Combination Therapy in Advanced HPV16-Positive Cancer Patients which Show 75% Survival of ICI Naïve Patients at 36 Months - Nov 9th, 2023 1:00 pm
PDS Biotechnology Announces Conference Call and Webcast for Third Quarter 2023 Financial Results - Nov 7th, 2023 1:00 pm
PDS Biotech Announces Preliminary Biomarker Study Results in Subset of Advanced HPV-Positive Head and Neck Cancer Patients at ESMO - Oct 23rd, 2023 12:00 pm
PDS Biotech Announces Interim Safety and Immune Response Data from Phase 1/2 Clinical Trial Evaluating Novel Antibody Drug Conjugate PDS0301 Combined with Docetaxel to Treat Metastatic Prostate Cancer - Oct 11th, 2023 12:00 pm